NYSE:BDX - Becton, Dickinson and Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $276.75
  • Forecasted Upside: 15.21 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$240.22
▼ -0.1 (-0.04%)

This chart shows the closing price for BDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Becton, Dickinson and Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BDX

Analyst Price Target is $276.75
▲ +15.21% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Becton, Dickinson and in the last 3 months. The average price target is $276.75, with a high forecast of $297.00 and a low forecast of $260.00. The average price target represents a 15.21% upside from the last price of $240.22.

This chart shows the closing price for BDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 contributing investment analysts is to buy stock in Becton, Dickinson and. This rating has held steady since April 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
12/31/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 0 sell ratings
3/30/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 0 sell ratings
6/28/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 0 sell ratings
9/26/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 0 sell ratings
12/25/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 0 sell ratings
3/25/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/24/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
6/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2021BarclaysInitiated CoverageEqual Weight$270.00Medium
5/7/2021SVB LeerinkLower Price TargetMarket Perform$270.00 ➝ $260.00High
2/5/2021CitigroupBoost Price TargetNeutral$273.00 ➝ $280.00Low
2/4/2021Piper SandlerBoost Price TargetPositive ➝ Overweight$275.00 ➝ $280.00Low
1/29/2021Raymond JamesBoost Price TargetOutperform$270.00 ➝ $282.00Low
12/15/2020The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyMedium
12/15/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$265.00Medium
12/15/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$262.00 ➝ $297.00Medium
11/6/2020Morgan StanleyLower Price TargetEqual Weight$270.00 ➝ $262.00Low
10/12/2020Raymond JamesLower Price TargetOutperform$285.00 ➝ $270.00Low
10/2/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyMedium
8/27/2020Morgan StanleyLower Price TargetEqual Weight$285.00 ➝ $270.00High
8/10/2020UBS GroupBoost Price TargetNeutral$265.00 ➝ $280.00Low
8/10/2020Morgan StanleyBoost Price TargetEqual Weight$248.00 ➝ $285.00Low
8/7/2020Raymond JamesBoost Price TargetOutperform$265.00 ➝ $285.00Medium
7/15/2020SVB LeerinkBoost Price TargetMarket Perform$262.00 ➝ $277.00Medium
7/9/2020BarclaysUpgradeEqual Weight ➝ Overweight$300.00Medium
7/2/2020William BlairReiterated RatingOutperformLow
6/25/2020Morgan StanleyLower Price TargetEqual Weight$255.00 ➝ $248.00High
6/25/2020Raymond JamesLower Price TargetPositive ➝ Outperform$290.00 ➝ $265.00High
5/31/2020The Goldman Sachs GroupInitiated CoverageBuy$278.00Low
5/14/2020Piper SandlerBoost Price TargetOverweight$286.00 ➝ $296.00Low
5/12/2020KeyCorpReiterated RatingHoldLow
5/8/2020SVB LeerinkReiterated RatingMarket Perform$245.00 ➝ $262.00Low
5/8/2020CfraLower Price TargetHold$285.00 ➝ $278.00Medium
5/8/2020UBS GroupBoost Price TargetNeutral$260.00 ➝ $265.00Medium
5/8/2020Stifel NicolausBoost Price TargetBuy$265.00 ➝ $280.00Medium
5/8/2020Raymond JamesBoost Price TargetOutperform$283.00 ➝ $290.00Low
5/8/2020CitigroupBoost Price TargetNeutral$234.00 ➝ $260.00Low
5/8/2020Wells Fargo & CompanyReiterated RatingBuyLow
4/14/2020BarclaysReiterated RatingHold$266.00Low
4/8/2020SVB LeerinkLower Price TargetMarket Perform$269.00 ➝ $245.00High
4/8/2020Wells Fargo & CompanyLower Price TargetOverweight$279.00 ➝ $270.00High
4/1/2020Stifel NicolausLower Price TargetBuy$280.00 ➝ $265.00Medium
3/27/2020CitigroupLower Price TargetNeutral$260.00 ➝ $234.00Medium
3/27/2020Morgan StanleyLower Price TargetEqual Weight$271.00 ➝ $255.00Medium
3/4/2020CitigroupInitiated CoverageNeutral$260.00Medium
2/7/2020Morgan StanleyLower Price TargetHold ➝ Equal Weight$287.00 ➝ $271.00Medium
2/7/2020Wells Fargo & CompanyLower Price TargetOverweight$285.00 ➝ $279.00Medium
2/7/2020Raymond JamesDowngradeStrong-Buy ➝ Outperform$288.00 ➝ $283.00Medium
2/6/2020CowenDowngradeOutperform ➝ Market Perform$306.00 ➝ $275.00High
2/6/2020Piper SandlerBoost Price TargetOverweight$279.00 ➝ $285.00High
2/6/2020CfraDowngradeBuy ➝ Hold$304.00 ➝ $285.00High
2/3/2020CowenReiterated RatingOutperform ➝ Outperform$255.00 ➝ $305.00High
1/22/2020KeyCorpBoost Price TargetOverweight$284.00 ➝ $298.00Low
1/8/2020BarclaysDowngradeOverweight ➝ Equal Weight$275.00Low
12/20/2019JPMorgan Chase & Co.Boost Price TargetOverweight$285.00 ➝ $300.00Low
12/17/2019Morgan StanleyBoost Price TargetEqual Weight$261.00 ➝ $287.00Low
12/16/2019Stifel NicolausBoost Price TargetBuy$275.00 ➝ $295.00Low
11/13/2019KeyCorpLower Price TargetOverweight$262.00 ➝ $256.00Medium
9/6/2019Wells Fargo & CompanyBoost Price TargetOutperform$270.00 ➝ $290.00N/A
9/5/2019Wells Fargo & CompanyReiterated RatingBuyLow
8/6/2019Piper Jaffray CompaniesLower Price TargetOverweight$267.00 ➝ $266.00Medium
7/16/2019Morgan StanleyBoost Price TargetEqual Weight$250.00 ➝ $261.00Low
6/28/2019Raymond JamesBoost Price TargetStrong-Buy$265.00 ➝ $288.00Low
5/13/2019Wells Fargo & CompanyLower Price TargetOutperform$280.00 ➝ $265.00Low
5/13/2019BarclaysUpgradeEqual Weight ➝ Overweight$266.00Low
5/10/2019BMO Capital MarketsLower Price TargetMarket Perform$272.00 ➝ $270.00Low
5/10/2019Morgan StanleyLower Price TargetEqual Weight$255.00 ➝ $250.00High
5/10/2019UBS GroupLower Price TargetNeutral$265.00 ➝ $250.00High
5/10/2019KeyCorpReiterated RatingPositive ➝ Overweight$273.00 ➝ $262.00High
4/15/2019BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$260.00 ➝ $266.00Low
3/19/2019Raymond JamesLower Price TargetStrong-Buy ➝ Strong-Buy$290.00 ➝ $280.00Medium
2/5/2019Piper Jaffray CompaniesBoost Price TargetOverweight$274.00Low
1/2/2019Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$265.00 ➝ $240.00Low
1/2/2019CitigroupLower Price TargetBuy ➝ Buy$279.00 ➝ $256.00Low
12/6/2018Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$280.00Medium
11/27/2018UBS GroupInitiated CoverageNeutral$260.00Medium
11/13/2018CitigroupLower Price TargetBuy ➝ Buy$289.00 ➝ $279.00Low
11/8/2018KeyCorpBoost Price TargetOverweight ➝ Overweight$264.00 ➝ $273.00Medium
11/8/2018BarclaysSet Price TargetHold$260.00Medium
11/7/2018Wells Fargo & CompanyLower Price TargetOutperform$290.00 ➝ $280.00High
11/6/2018Piper Jaffray CompaniesLower Price TargetOverweight$250.00Medium
10/15/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$278.00High
10/4/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$250.00 ➝ $280.00High
9/6/2018Wells Fargo & CompanyBoost Price TargetOutperform$275.00 ➝ $290.00Low
8/8/2018CitigroupBoost Price TargetBuy ➝ Buy$274.00 ➝ $283.00Medium
8/3/2018Royal Bank of CanadaReiterated RatingHold$248.00Low
8/3/2018KeyCorpReiterated RatingBuy$264.00Low
6/21/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$175.00Medium
4/10/2018CitigroupUpgradeNeutral ➝ Buy$237.00 ➝ $251.00Low
3/5/2018BMO Capital MarketsInitiated CoverageMarket Perform$249.00Low
2/7/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$245.00 ➝ $250.00Low
2/6/2018Piper Jaffray CompaniesReiterated RatingOverweight$223.00 ➝ $260.00Low
1/19/2018Bank of AmericaReiterated RatingBuy ➝ Buy$260.00Medium
1/5/2018CitigroupUpgradeSell ➝ NeutralLow
1/5/2018KeyCorpInitiated CoverageOverweight ➝ Overweight$260.00Low
1/3/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$245.00Medium
12/29/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy ➝ Buy$239.00 ➝ $260.00Low
12/14/2017ArgusBoost Price TargetAverage ➝ Buy$235.00Low
11/3/2017Stifel NicolausReiterated RatingBuy$245.00N/A
11/3/2017Morgan StanleyBoost Price TargetEqual Weight$205.00 ➝ $245.00N/A
11/3/2017Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$210.00 ➝ $230.00N/A
10/25/2017Royal Bank of CanadaReiterated RatingHold$210.00N/A
10/24/2017Wells Fargo & CompanyReiterated RatingOutperform ➝ Positive$225.00 ➝ $235.00N/A
9/22/2017Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$225.00Low
9/12/2017Piper Jaffray CompaniesReiterated RatingBuy$213.00High
8/14/2017CowenReiterated RatingBuy$230.00Low
8/10/2017BarclaysReiterated RatingEqual Weight$205.00 ➝ $210.00Low
8/9/2017Stifel NicolausReiterated RatingBuyLow
7/21/2017Bank of AmericaReiterated RatingBuy$200.00 ➝ $225.00Medium
7/10/2017CowenReiterated RatingOutperform$200.00 ➝ $230.00Low
6/30/2017Raymond JamesUpgradeOutperform ➝ Strong-Buy$210.00 ➝ $180.00Low
4/24/2017Evercore ISIUpgradeIn-Line ➝ Outperform$186.00 ➝ $200.00High
4/13/2017Royal Bank of CanadaReiterated RatingHold$177.00Low
3/29/2017Jefferies Financial GroupReiterated RatingBuy$200.00Low
1/6/2017Royal Bank of CanadaReiterated RatingHold$177.00N/A
1/5/2017Raymond JamesReiterated RatingStrong-Buy ➝ Outperform$200.00 ➝ $180.00N/A
1/5/2017UBS GroupDowngradeStrong-Buy ➝ OutperformN/A
1/3/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$190.00 ➝ $175.00N/A
11/21/2016SVB LeerinkReiterated RatingMarket Perform$180.00 ➝ $185.00N/A
11/18/2016UBS GroupReiterated RatingBuy$195.00N/A
11/4/2016Deutsche Bank AktiengesellschaftReiterated RatingBuy$197.00 ➝ $189.00N/A
10/21/2016ArgusReiterated RatingBuy$185.00N/A
9/23/2016CitigroupDowngradeNeutral ➝ Sell$167.00 ➝ $165.00N/A
8/16/2016CowenReiterated RatingOutperform$185.00N/A
8/9/2016SVB LeerinkReiterated RatingHoldN/A
8/5/2016Jefferies Financial GroupReiterated RatingBuyN/A
8/5/2016UBS GroupBoost Price TargetBuy$182.00 ➝ $195.00N/A
7/28/2016Jefferies Financial GroupBoost Price TargetBuy$190.00 ➝ $192.00N/A
7/12/2016Bank of AmericaReiterated RatingBuyN/A
(Data available from 6/23/2016 forward)
Becton, Dickinson and logo
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Read More

Today's Range

Now: $240.22
Low: $238.85
High: $241.48

50 Day Range

MA: $246.08
Low: $238.68
High: $260.94

52 Week Range

Now: $240.22
Low: $219.50
High: $284.97

Volume

1,396,275 shs

Average Volume

1,396,144 shs

Market Capitalization

$69.86 billion

P/E Ratio

42.74

Dividend Yield

1.38%

Beta

0.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Becton, Dickinson and?

The following Wall Street sell-side analysts have issued reports on Becton, Dickinson and in the last twelve months: Barclays PLC, Citigroup Inc., Morgan Stanley, Piper Sandler, Raymond James, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, UBS Group AG, Wells Fargo & Company, William Blair, and Zacks Investment Research.
View the latest analyst ratings for BDX.

What is the current price target for Becton, Dickinson and?

8 Wall Street analysts have set twelve-month price targets for Becton, Dickinson and in the last year. Their average twelve-month price target is $276.75, suggesting a possible upside of 15.2%. Morgan Stanley has the highest price target set, predicting BDX will reach $297.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $260.00 for Becton, Dickinson and in the next year.
View the latest price targets for BDX.

What is the current consensus analyst rating for Becton, Dickinson and?

Becton, Dickinson and currently has 5 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BDX will outperform the market and that investors should add to their positions of Becton, Dickinson and.
View the latest ratings for BDX.

What other companies compete with Becton, Dickinson and?

How do I contact Becton, Dickinson and's investor relations team?

Becton, Dickinson and's physical mailing address is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. The medical instruments supplier's listed phone number is 201-847-6800. The official website for Becton, Dickinson and is www.bd.com.